Taking on-board the Alexion acquisition
21/07/21 -"AstraZeneca has completed the acquisition of Alexion Pharmaceuticals (US rare diseases specialist). Given that rare diseases are a high-growth and attractive margin area (even ahead of oncology), ..."
Pages
70
Language
English
Published on
21/07/21
You may also be interested by these reports :
20/08/26
Moderna’s late-stage skin cancer vaccine success nearly tripled its share price yesterday and opened a new realm within cancer treatment. Other ...
14/08/26
Since we last teased this name on 3 January 2025 — arguing there was little incremental upside left after a strong run and a post-merger valuation ...
04/08/26
Imagine a restaurant having to serve its customers by ordering outside food. We cannot resist drawing parallels between this hypothetical scenario ...
07/07/26
Following the June 2026 phase III R&D setback for an investigational drug, Riliprubart, targeting a rare neurological disease called CIDP (chronic ...